Tyrosine Kinase Inhibitor Therapy: Resistance and Mutation Detection in
Chronic Myeloid Leukemia Patients

The BCR-ABL1 fusion gene in the Philadelphia Chromosome, formed due to translocation between chromosome 9 and 22, leads to occurrence of Chronic Myeloid Leukemia. This is responsible for up to 15% of adult leukemia’s. Most patients treated with Tyrosine Kinase Inhibitor [TKI] imatinib mesylate achieve durable response but may undergo relapse at some stage. One of the mechanisms that may confer TKI resistance is Point mutation within BCR-ABL kinase and regulatory domain. We aim to focus on the TKIs, presence of mutations and identify the techniques used to detect the occurrence of the same in brief.

Descargo de responsabilidad: este resumen se tradujo utilizando herramientas de inteligencia artificial y aún no ha sido revisado ni verificado

Revista internacional de desarrollo e investigación de fármacos

Indexado en

Comparte esta página

Abstracto

Tyrosine Kinase Inhibitor Therapy: Resistance and Mutation Detection in Chronic Myeloid Leukemia Patients